Current Breast Cancer Reports

, Volume 1, Issue 1, pp 29–41 | Cite as

Concurrent use of chemotherapy or novel agents in combination with radiation in breast cancer

  • Kevin Kalinsky
  • Alice Ho
  • Christopher A. Barker
  • Andrew Seidman
Article
  • 138 Downloads

Abstract

Treating breast cancer patients concurrently with chemotherapy and radiation is a potentially attractive approach. The goal is to develop strategies that enhance the effects of each modality while minimizing toxicity. Most data evaluating the role of simultaneous therapy have been generated from small phase 1 and 2 trials. As few prospective, randomized controlled trials have been performed in this area, generating definitive conclusions regarding the efficacy and toxicity from combined therapy remains difficult. This article reviews the current literature on the benefits and toxicities of concurrent radiation with cytotoxic chemotherapy, as well as with novel biologic agents such as monoclonal antibodies, tyrosine kinase inhibitors, and heat shock protein antagonists. Because the appropriate use of concurrent radiation with chemotherapy and biologic agents continues to evolve, we also highlight future and ongoing trials evaluating this treatment option.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Choy H: Taxanes in combined modality therapy for solid tumors. Crit Rev Oncol Hematol 2001, 37:237–247.PubMedCrossRefGoogle Scholar
  2. 2.
    Bellon J, Come S, Gelman R, et al.: Sequencing of chemotherapy and radiation therapy in early stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol 2005, 23:1934–1940.PubMedCrossRefGoogle Scholar
  3. 3.
    Bucholz T, Austin-Seymour M, Moe R, et al.: Effect of delay in radiation in combined modality treatment of breast cancer. Int J Radiat Oncol Biol Phys 1993, 26:23–55.Google Scholar
  4. 4.
    Steel G: Terminology in the description of drug-radiation interactions. Int J Radiat Oncol Biol Phys 1979, 5:1145–1150.PubMedGoogle Scholar
  5. 5.
    Steel G, Peckham M: Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979, 5:85–91.PubMedGoogle Scholar
  6. 6.
    Seiwert T, Salama J, Vokes E: The concurrent chemoradiation paradigm—general principles. Nat Clin Pract Oncol 2007, 4, 86–100.PubMedCrossRefGoogle Scholar
  7. 7.
    Livi L, Saieva C, Borhesi S, et al.: Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for early breast carcinoma. Int J Radiat Oncol Biol Phys 2008, 71:705–709.PubMedGoogle Scholar
  8. 8.
    Montemurro F, Gatti M, Redana S, et al.: Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer. J Chemother 2006, 18:90–97.PubMedGoogle Scholar
  9. 9.
    Isaac N, Panzarella T, Lau A, et al.: Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen. Cancer 2002, 95:696–703.PubMedCrossRefGoogle Scholar
  10. 10.
    Ung O, Langlands AO, Barraclough B, Boyages J: Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement. J Clin Oncol 1995, 13:435–443.PubMedGoogle Scholar
  11. 11.
    Arcangeli G, Pinnaro P, Rambone R, et al.: A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer. Int J Radiat Oncol Biol Phys 2006, 64:161–167.PubMedGoogle Scholar
  12. 12.
    Novak R, Kharas C: Mitoxantrone: propensity for free radical formation and lipid peroxidation. Implication for cardiotoxicity. Invest New Drugs 1985, 3:95–96.PubMedCrossRefGoogle Scholar
  13. 13.
    Rouëssé J, De la Lande B, Bertheault-Cvitkovic F, et al.: A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results. Int J Radiat Oncol Biol Phys 2006, 64:1072–1080.PubMedGoogle Scholar
  14. 14.
    Toledano A, Azria D, Garaud P, et al.: Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial. J Clin Oncol 2007, 25:405–410.PubMedCrossRefGoogle Scholar
  15. 15.
    Toledano A, Bollet M, Forquet A, et al.: Does concurrent radiochemotherapy affect cosmetic results in the adjuvant setting after breast-conserving surgery? Results of the ARCOSEIN multicenter, phase III study: patients’ and doctors’ views. Int J Radiat Oncol Biol Phys 2007, 68:66–72.PubMedGoogle Scholar
  16. 16.
    Gluck S: Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin. Oncologist 2005, 10:780–791.PubMedCrossRefGoogle Scholar
  17. 17.
    Berthiaume J, Wallace K: Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol 2007, 1:15–25.CrossRefGoogle Scholar
  18. 18.
    Milas L, Milas MM, Mason KA: Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol 1999, 9:12–26.PubMedGoogle Scholar
  19. 19.
    Mason KA, Hunter NR, Milas M, et al.: Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 1997, 3:2431–2438.PubMedGoogle Scholar
  20. 20.
    Talwar N, Redpath JL: Schedule dependence of the interaction of radiation and Taxol in Hela cells. Radiat Res 1997, 148:48–53.PubMedCrossRefGoogle Scholar
  21. 21.
    Burstein H, Bellon J, Galper S, et al.: Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for stage II or III breast cancer. Int J Radiat Oncol Biol Phys 2006, 64:496–504.PubMedGoogle Scholar
  22. 22.
    Cox J, Stetz J, Pajak T: Toxicity criteria of the Radiation Therapy Oncology Research Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995, 31:1341–1346.PubMedGoogle Scholar
  23. 23.
    Sporano J, Wang M, Martion S, et al.: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008, 358:1663–1671.CrossRefGoogle Scholar
  24. 24.
    Taghian A, Assaad S, Niemierko A, et al.: Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst 2001, 93:1806–1811.PubMedCrossRefGoogle Scholar
  25. 25.
    Lingos T, Recht A, Vicini A, et al.: Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys 1991, 21:355–360.PubMedGoogle Scholar
  26. 26.
    Yu T, Whitman G, Thames H, et al.: Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiation in breast cancer patients. J Natl Cancer Inst 2004, 96:1676–1681.PubMedGoogle Scholar
  27. 27.
    Beal K, Hudis C, Norton L, et al.: Radiation pneumonitis in breast cancer patients treated with taxanes: does sequential radiation therapy lower the risk? Breast J 2005, 11:317–320.PubMedCrossRefGoogle Scholar
  28. 28.
    Hanna Y, Baglan K, Stromgber J, et al.: Acute and subacute toxicity associated with concurrent adjuvant radiation therapy and paclitaxel in primary breast cancer therapy. Breast J 2002, 8:149–153.PubMedCrossRefGoogle Scholar
  29. 29.
    Taghian A, Assaad S, Nemierko A, et al.: Is a reduction in radiation lung volume and dose necessary with paclitaxel chemotherapy for node-positive breast cancer? Int J Radiat Oncol Biol Phys 2005, 62:386–391.PubMedGoogle Scholar
  30. 30.
    Bellon J, Lindsley K, Ellis G, et al.: Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer. Int J Radiat Oncol Biol Phys 2000, 48:393–397.PubMedGoogle Scholar
  31. 31.
    Ellerbroek N, Martino S, Mautner B, et al.: Breast-conserving therapy with adjuvant paclitaxel and radiation therapy: feasibility of concurrent treatment. Breast J 2003, 9:74–78.PubMedCrossRefGoogle Scholar
  32. 32.
    Buzdar A, Singletary S, Theriault R, et al.: Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999, 17:3412–3417.PubMedGoogle Scholar
  33. 33.
    Formenti SC, Dunnington G, Uzieli B, et al.: Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy. Int J Radiat Oncol Biol Phys 1997, 39:1059–1068.PubMedGoogle Scholar
  34. 34.
    Formenti S, Volm M, Skinner K, et al.: Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. J Clin Oncol 2003, 21:864–870.PubMedCrossRefGoogle Scholar
  35. 35.
    Chakravarthy B, Kellye M, McLaren, et al.: Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer. Clin Cancer Res 2006, 12:1570–1576.PubMedCrossRefGoogle Scholar
  36. 36.
    Kao J, Conzen S, Jaskowiak N, et al.: Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials. Int J Radiat Oncol Biol Phys 2005, 61:1045–1053.PubMedGoogle Scholar
  37. 37.
    Tapen E, Halberg F, Champion L, et al.: Treatment of locally recurrent or high-risk carcinoma of the breast with radiation therapy and weekly docetaxel given as a radiosensitizer [abstract 11538]. J Clin Oncol 2008, 26(May 20 Suppl).Google Scholar
  38. 38.
    Glynne-Jones R, Dunst J, Sebag-Montefiore D: The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been? Ann Oncol 2006, 17:361–371.PubMedCrossRefGoogle Scholar
  39. 39.
    Gaui MF, Amorim G, Arcuri RA, et al.: A phase II study of second-line neoadjuvant chemotherapy with capecitabine and radiation therapy for anthracycline-resistant locally advanced breast cancer. Am J Clin Oncol 2007, 30:78–81.PubMedCrossRefGoogle Scholar
  40. 40.
    Schüller J, Cassidy J, Dumont E, et al.: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000, 45:291–297.PubMedCrossRefGoogle Scholar
  41. 41.
    Miwa M, Ura M, Nishida M, et al.: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998, 34:1274–1281.PubMedCrossRefGoogle Scholar
  42. 42.
    Verso M, Agnelli G: Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003, 21:3665–3675.PubMedCrossRefGoogle Scholar
  43. 43.
    Clark DR, Raffin TA: Infectious complications of indwelling long-term central venous catheters. Chest 1990, 97:966–972.CrossRefGoogle Scholar
  44. 44.
    Huang E, Buzdar AU, Buhholz TA, et al.: Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. Int J Radiat Oncol Biol Phys 2002, 53:1225–1233.PubMedCrossRefGoogle Scholar
  45. 45.
    National Cancer Institute. Bethesda, MD. Available at http://www.cancer.gov. Accessed in January 2009.
  46. 46.
    Seidman A, Gollamudi S: Combining chemotherapy and radiotherapy for metastatic breast cancer: opportunities and obstacles. Adv Oncol 1998, 14:25–29.Google Scholar
  47. 47.
    Karasawa K, Katsui K, Seki K, et al.: Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer. Breast Cancer 2003, 10:268–274.PubMedCrossRefGoogle Scholar
  48. 48.
    Mehta M, Rodrigus P, Terhaard C, et al.: Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003, 21:2529–2536.PubMedCrossRefGoogle Scholar
  49. 49.
    Meyers CA, Boake C: Neurobehavioral disorders experienced by brain tumor patients: rehabilitation strategies. Cancer Bull 1993, 45:362–364.Google Scholar
  50. 50.
    Carde P, Timmerman R, Mehta MP, et al.: Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 2001, 19:2074–2083.PubMedGoogle Scholar
  51. 51.
    Bonner J, Harari P, Giralt J, et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567–578.PubMedCrossRefGoogle Scholar
  52. 52.
    Liang K, Lu Y, Jin W, et al.: Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther 2003, 2:1113–1120.PubMedGoogle Scholar
  53. 53.
    Halyard M, Pisansky T, Solin L, et al.: Adjuvant radiotherapy and trastuzumab in stage I-IIA breast cancer: toxicity data from North Central Cancer Treatment Group Phase III trial N9831 [abstract 523]. J Clin Oncol 2006, ASCO Annual Meeting Proceedings Part 1; 24(18s).Google Scholar
  54. 54.
    Romond E, Perez E, Bryan J, et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673–1684.PubMedCrossRefGoogle Scholar
  55. 55.
    Boughey J, Gonzalez R, Bonner E, et al.: Current treatment and clinical trial developments for ductal carcinoma in situ of the breast. Oncologist 2007, 12:1276–1287.PubMedCrossRefGoogle Scholar
  56. 56.
    Vargas M, Valduvieco I, Almendro V, et al.: Radiosensitivity enhancement by dual HER-1/2 inhibitor (GW572016) in SKBR3 human breast carcinoma HER-2+ cell line [abstract 22112]. J Clin Oncol 2008, 26(2008 Suppl).Google Scholar
  57. 57.
    Stewart D, Mikhael N, Nair R, et al.: Platinum concentrations in human autopsy tumor samples. Am J Clin Oncol 1988, 11:152–158.PubMedCrossRefGoogle Scholar
  58. 58.
    Stewart D, Molepo J, Green R, et al.: Factors affecting platinum concentrations in human surgical tumour specimens after cisplatin. Br J Cancer 1995, 71:598–604.PubMedGoogle Scholar
  59. 59.
    Zwolak P, Dudek A, Bodempudi V, et al.: Local irradiation in combination with bevacizumab enhances radiation control of bone destruction and cancer-induced pain in a model of bone metastases. Int J Cancer 2008, 122:681–688.PubMedCrossRefGoogle Scholar
  60. 60.
    Bull E, Dote H, Brady K, et al.: Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Clin Cancer Res 2004, 10:8077–8084.PubMedCrossRefGoogle Scholar
  61. 61.
    Taldone T, Gozman A, Maharaj R, et al.: Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 2008, 8:370–374.PubMedCrossRefGoogle Scholar
  62. 62.
    Peng X, Karna P, O’Regan R, et al.: Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells. Mol Pharmacol 2007, 71:101–111.PubMedCrossRefGoogle Scholar
  63. 63.
    Yi T, Li H, Wang X, et al.: Enhancement radiosensitization of breast cancer cells by deguelin. Cancer Biother Radiopharm 2008, 23:355–362.PubMedCrossRefGoogle Scholar
  64. 64.
    Jiao Y, Wang H, Fan S: Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin 2007, 28:1957–1967.PubMedCrossRefGoogle Scholar
  65. 65.
    Cox JD, Stetz J, Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995, 31:1341–1346.PubMedGoogle Scholar
  66. 66.
    Milas L, Milas MM, Mason KA: Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol 1999, 9:12–26.PubMedGoogle Scholar
  67. 67.
    Wiedenmann N, Valdecanas D, Hunter N, et al.: 130-nm Albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain. Clin Cancer Res 2007, 13:1868–1874.PubMedCrossRefGoogle Scholar
  68. 68.
    Duda DG, Jain RK, Willett CG: Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 2007, 25:4033–4042.PubMedCrossRefGoogle Scholar
  69. 69.
    Shewach DS, Lawrence TS: Antimetabolite radiosensitizers. J Clin Oncol 2007, 25:4043–4050.PubMedCrossRefGoogle Scholar
  70. 70.
    Wilson GD, Bentzen SM, Harari PM: Biologic basis for combining drugs with radiation. Semin Radiat Oncol 2006, 16:2–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Begg AC, Fu KK, Shrieve DC, et al.: Combination therapy of a solid murine tumor with cyclophosphamide and radiation: the effects of time, dose and assay method. Int J Radiat Oncol Biol Phys 1979, 5:1433–1439.PubMedGoogle Scholar
  72. 72.
    Bonner JA, Lawrence TS: Doxorubicin decreases the repair of radiation-induced DNA damage. Int J Radiat Biol 1990, 57:55–64.PubMedCrossRefGoogle Scholar
  73. 73.
    Chen AY, Chou R, Shih SJ, et al.: Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs. Crit Rev Oncol Hematol 2004, 50:111–119.PubMedCrossRefGoogle Scholar
  74. 74.
    Harari PM, Allen GW, and Bonner JA: Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol 2007, 25:4057–4065.PubMedCrossRefGoogle Scholar
  75. 75.
    Berry RJ: Effects of some metabolic inhibitors on x-ray dose-response curves for the survival of mammalian cells in vitro, and on early recovery between fractionated x-ray doses. Br J Radiol 1966, 39:458–463.PubMedCrossRefGoogle Scholar
  76. 76.
    Von der Maase H: Interactions of radiation and 5-fluorouracil, cyclophosphamide or methotrexate in intestinal crypt cells. Int J Radiat Oncol Biol Phys 1984, 10:77–86.PubMedGoogle Scholar
  77. 77.
    Pietras RJ, Poen JC, Gallardo D, et al.: Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 1999, 59:1347–1355.PubMedGoogle Scholar
  78. 78.
    Simoens C, Lardon F, Pauwels B, et al.: Comparative study of the radiosensitizing and cell cycle effects of vinflunine and radiosensitizing and cell cycle effects of vinflunine and vinorelbine, in vitro. BMC Cancer 2008, 8:65.PubMedCrossRefGoogle Scholar
  79. 79.
    Fukuoka K, Arioka H, Iwamoto Y, et al.: Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells. Lung Cancer 2001, 34:451–460.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  • Kevin Kalinsky
  • Alice Ho
  • Christopher A. Barker
  • Andrew Seidman
    • 1
  1. 1.Breast Cancer Medicine ServiceMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations